Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
Truist Securities analyst Supawat Thongthip reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $35 to $40.
Truist Securities analyst Supawat Thongthip reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $35 to $40.